导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.30% | 3344/4773 |
| 近一周 | -1.53% | 2278/5465 |
| 近一月 | -3.24% | 2302/5421 |
| 近一季 | -6.96% | 2601/5231 |
| 近半年 | -1.96% | 1962/4920 |
| 近一年 | -2.38% | 3042/4394 |
| 近两年 | 32.31% | 2198/2954 |
| 近三年 | 19.86% | 1492/2253 |
| 成立以来 | 214.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.55% 3647/4961 |
7.81% 2663/5312 |
- - |
- - |
| 2025 | 15.03% 2575/4813 |
-1.05% 2560/3635 |
2.57% 1483/4076 |
11.84% 3125/4524 |
1.35% 1406/4813 |
| 2024 | 19.74% 505/3463 |
5.09% 404/2808 |
0.20% 641/3014 |
17.48% 1183/3129 |
-3.20% 2290/3463 |
| 2023 | -10.21% 1276/2656 |
1.76% 1519/2280 |
-4.04% 1021/2385 |
0.11% 389/2515 |
-8.15% 2256/2655 |
| 2022 | -12.56% 289/2207 |
-11.46% 515/1919 |
10.33% 262/2016 |
-11.92% 612/2113 |
1.62% 1197/2208 |
| 2021 | 0.26% 720/1822 |
0.56% 286/1255 |
3.90% 945/1330 |
-6.73% 983/1466 |
2.89% 501/1822 |
| 2020 | 42.16% 273/1250 |
-9.87% 724/1028 |
14.51% 550/1067 |
17.91% 94/1164 |
16.82% 149/1184 |
| 2019 | 44.30% 173/1092 |
24.67% 495/754 |
4.49% 26/804 |
3.40% 254/850 |
7.13% 481/918 |
| 2018 | -17.69% 131/834 |
- - |
- - |
- - |
-11.82% 357/691 |
| 2017 | 35.96% 34/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.65% 146/605 |
- - |
- - |
- - |
- - |
| 2015 | -7.00% 281/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华润元大富时中国A50指数A VS. 长安沪深300非周期A(740101) |